English Community

Hello teal sisters,

I wanted to share the news about a potential new treatment for platinum resistant ovarian cancer and endometrial cancer.

Good results from the phase 1 trial (BEHOLD-1) and now being fast tracked to phase 3 trials.

The name of the drug is mocertatug rezetecan (Mo-Rez) and it is an antibody-drug conjugate. 

Upcoming trial information:

Mo-Rez will advance to five pivotal
global phase III trials in 2026, starting with PROC (BEHOLD-Ovarian01 / NCT07286266) and 2L EC (BEHOLDEndometrial01 / NCT07286331). Additional phase III studies will evaluate Mo‑Rez in platinum‑sensitive ovarian cancer
(BEHOLD-Ovarian02) and in first‑line maintenance settings for ovarian cancer without homologous recombination
deficiency (BEHOLD-Ovarian03) and mismatch‑repair–proficient endometrial cancer (BEHOLD-Endometrial02).

Here's the link to the press release:

https://www.gsk.com/media/eumhphoe/mo-rez-behold-1-data-press-release-12-april.pdf

@wisdomseeker thank you.  I always love hearing there is new treatments in the works.

Thanks @wisdomseeker. Hopefully it will make it's way to Canada from the UK in the near term. Appreciate you sharing.

#Clinicaltrialsandresearch

@brendalee was this the thread you were just referencing??